title: Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Wolf
authors.forename: David
authors.initials: D
authors.lastname: Siegel
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.forename: Katharine
authors.initials: K
authors.lastname: Hazell
authors.forename: Priscille M
authors.initials: PM
authors.lastname: Bourquelot
authors.forename: Bourras R
authors.initials: BR
authors.lastname: Bengoudifa
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Matous
authors.forename: Ravi
authors.initials: R
authors.lastname: Vij
authors.forename: Margarida
authors.initials: M
authors.lastname: de Magalhaes-Silverman
authors.forename: Rafat
authors.initials: R
authors.lastname: Abonour
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019540:Area Under Curve; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007211:Indoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077269:Lenalidomide; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D000077767:Panobinostat; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077767:Panobinostat; D000077269:Lenalidomide